Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.61 |
| ▸ | HTR1A | P08908 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16467730 | 0.88 | HTR2C (0.43) | HTR2C | |
| SCHEMBL613612 | 0.76 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30228461 | 0.76 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL30853595 | 0.75 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL307161 | 0.75 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2465607 | 0.72 | HTR1A (0.49) | HTR1A | |
| SCHEMBL7839191 | 0.71 | HTR2C (0.45) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30493303 | 0.70 | HTR2C (0.72) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL27833490 | 0.70 | HTR2C (0.62) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2783823 | 0.69 | HTR2C (0.73) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521614-B1 | Anticoagulant agents for treatment and prevention of thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-18 | — | — | US | disclosed |